Overview

A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment

Status:
Completed

Trial end date:
2021-07-19

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the recommended Phase 2 dose and evaluate safety profile of cusatuzumab in combination with azacitidine in Japanese participants with treatment naïve acute myeloid leukemia (AML) who are not candidates for intensive treatment.

Phase:

Phase 1

Details

Lead Sponsor:

Janssen Pharmaceutical K.K.

Collaborators:

argenx
argenx BVBA

Treatments:

Azacitidine